Cyclic progestin therapy for the management of mastopathy and mastodynia

  title={Cyclic progestin therapy for the management of mastopathy and mastodynia},
  author={Ulrich H. Winkler and Andreas Schindler and Ulrich Brinkmann and C Ebert and Carsten Oberhoff},
  journal={Gynecological Endocrinology},
  pages={37 - 43}
The management of benign diseases of the breast aims to halt the progression of fibrocystic transformation and to eliminate the symptoms of pain and breast tenderness. Progestins can be used for this purpose. In a controlled, randomized, double-blind, parallel-group study we treated 31 women with mastopathy/mastodynia with the progestins medrogestone (10 mg/day) or dydrogesterone (10 mg/day) from day 14 to day 25 for six cycles. Before, during and at the end of therapy the following parameters… 

The Influence of Progesterone Gel Therapy in the Treatment of Fibrocystic Breast Disease

Mastalgia and mastodynia significantly decreased during the local p gel therapy, and there was a significantly lower number and size of the cysts in patients with FBD.

Dienogest and the breast

In a clinical pilot study, 21 women with endometriosis have been primarely treated with dienogest 2 × 10 mg daily p.o.s. for 24 weeks and the action of such high-dose progestogen treatment on the breast was evaluated by breast ultrasound prior to medication and at 24 weeks of medical treatment.

Evaluation and management of breast pain.

Most patients with breast pain respond favorably to a combination of reassurance and nonpharmacological measures, and the medications danazol, tamoxifen, and bromocriptine are effective; however, the potentially serious adverse effects of these medications limit their use to selected patients with severe, sustained breast pain.

The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia

  • P. RegidorE. Colli
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2022
The progestins 4 mg and desogestrel 0,075’mg showed a marked effect in the non-contraceptive aspects of dysmenorrhea and mastodynia so that new possibilities are opened for these two benign gynecological diseases.

Dydrogesterone and other progestins in benign breast disease: an overview

  • A. Schindler
  • Medicine
    Archives of Gynecology and Obstetrics
  • 2010
In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical examination and follow-up including breast ultrasound.

The relationship between using estrogen and/or progesterone and the risk of mammary gland hyperplasia in women: a meta-analysis

This study findings indicated that using estrogen and/or progesterone might increase the risk of MGH in premenopausal and postmenopausal women.

Molecular screening of Chinese medicinal plants for progestogenic and anti-progestogenic activity

This discovery will aid selection of suitable herbs for hormone replacement therapy as none of the herb extracts shown significant toxic effect on PAE cells at 40–100 μg/mL compared to control.



Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management.

  • H. Vorherr
  • Medicine, Biology
    American journal of obstetrics and gynecology
  • 1986

Treatment of premenstrual syndrome. A double-blind trial of dydrogesterone.

Medical management of mammary dysplasia.

The efficacy of therapeutic regimens used in the management of patients with mammary dysplasia is reviewed and a rational approach is recommended.

The effect of dydrogesterone on premenstrual symptoms. A double-blind, randomized, placebo-controlled study in general practice.

A significant effect of dydrogesterone was found on decreased libido, and statistical significance was nearly achieved for the symptoms irritability and headache.

Serum Prolactin Levels in Patients With Fibrocystic Breast Disease

Results indicate that a high proportion of patients with fibrocystic breast disease exhibit increased daily prolactin secretion, and the response to TRH stimulation was significantly higher in the study patients than in the controls.

Effect of high-dose progesterone on the pre-menstrual syndrome; a double-blind cross-over trial

A double-blind cross-over placebo controlled trial was carried out to compare progesterone 200 mg with a placebo, both given in rectal suppositories, in 20 patients with the pre-menstrual syndrome

Elevated peripheral levels of androgens and of some steroid sensitive plasma proteins in patients with severe fibrocystic breast disease

It was of interest to investigate further the endocrine status in the FBD patient, especially concerning androgens, since in non-pregnant women changes in the androgen status affect SHBG levels more than do estrogen alterations.